USE OF COMPOSITION IN TREATING ATHEROSCLEROSIS
20230104799 · 2023-04-06
Inventors
Cpc classification
A61K9/0019
HUMAN NECESSITIES
A61K47/6925
HUMAN NECESSITIES
A61P9/10
HUMAN NECESSITIES
International classification
A61K41/00
HUMAN NECESSITIES
A61K47/69
HUMAN NECESSITIES
A61K9/00
HUMAN NECESSITIES
Abstract
Disclosed in the present application is a use of a composition in treating atherosclerosis. Specifically, the present application relates to a use of a composition comprising microbubbles and copper ions in treating atherosclerosis.
Claims
1. A method for treatment of atherosclerosis, comprising: injecting a composition into a blood vessel of a subject in need of the treatment, and applying external energy to a vascular site to be treated, the composition comprising microbubbles and copper ions.
2. The method according to claim 1, wherein the composition comprises: a solution comprising microbubbles having a concentration greater than 1×10.sup.6 /mL and a particle size less than 10 μm and an effective therapeutic amount of copper ions, wherein the microbubble has a core-envelope structure, the core of the microbubble contains a fluid, and the envelope of the microbubble is composed of a pharmaceutically acceptable film-forming material.
3. The method according to claim 1, wherein the fluid contained in the core of the microbubble has a boiling point under standard conditions of lower than 35° C., preferably a boiling point lower than 30° C., more preferably is one selected from air, carbon dioxide and C1-6 fluoroalkanes, particularly preferably is perfluoropropane.
4. The method according to claim 1, wherein the pharmaceutically acceptable film-forming material is albumin or a phospholipid material, preferably human serum albumin.
5. The method according to claim 1, wherein the copper ion and the pharmaceutically acceptable film-forming material form a complex, preferably a chelate.
6. The se method according to claim 1, wherein the surface of the envelope of the microbubble further has a targeting moiety, wherein the targeting moiety is a chemical group having a substituent that can chelate calcium, preferably the substituent is at least one selected from an amino group, a carboxyl group, a phosphoryl group, and a sulfydryl group, and more preferably, the targeting moiety has a bisphosphonate group.
7. The method according to claim 1, wherein the concentration of the microbubbles is 0.5×10.sup.7 to 1.5×10.sup.7/mL, preferably 1.0×10.sup.7 to 1.3×10.sup.7/mL.
8. The method according to claim 1, wherein the microbubbles have an average diameter of 1 to 5 μm, preferably 1 to 2 μm.
9. The method according to claim 1, wherein the effective therapeutic amount of Cu.sup.2+ is Cu.sup.2+ having a concentration of 35 to 105 mg/mL in the composition, preferably Cu.sup.2+ having a concentration of 45 to 85 mg/mL.
10. The method according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, preferably the carrier may be a dextrose solution, physiological saline or deionized water.
11. The method according to claim 10, wherein the medicament is an injection, preferably the medicament is an injection or a powder injection.
12. The method according to claim 1, wherein the microbubbles are cavitated under the action of external energy, preferably, the energy is ultrasonic energy or electromagnetic energy.
13. The method according to claim 1, wherein the treatment of atherosclerosis is inhibiting atherosclerotic plaque size growth and/or reducing atherosclerotic plaque size, preferably the atherosclerotic plaque is an atherosclerotic plaque at any stage.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
Specific Modes for Carrying Out the Embodiments
[0058] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention and the accompanying drawings, and obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by a person of ordinary skill in the art without creative labor shall fall within the protection scope of the present invention.
[0059] Throughout the description, unless otherwise specified, the terms used herein are to be understood as having the meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention pertains. In case of contradiction, the present description takes precedence.
[0060] It should be noted that in the Examples of the present invention, the terms “comprise”, “contain” or any other variations thereof are intended to cover non-exclusive inclusion, such that a method or apparatus that comprises a series of elements not only include those elements explicitly recited, but also other elements not explicitly recited, or inherent to the implementation of the method or apparatus. Without further limitation, an element defined by the phrase “comprising a . . . ” does not preclude the presence of additional related elements in the method or apparatus that includes the element.
[0061] The composition of the present invention can be prepared by the following method.
[0062] For example, a fluid forming the core of the microbubbles can be filled into a dextrose solution containing a certain concentration of human serum albumin and a certain concentration of copper-containing ion source, and vibrated and mixed in an ultrasonic crusher to obtain a stable existing microbubble solution system. In this system, copper ions are stably combined with human serum albumin in the form of complexes. In which the copper ion source can be a water-soluble copper salt, such as copper sulfate, copper nitrate, copper chloride and the like.
[0063] The method of preparing the microbubbles of the present invention is not limited to the methods exemplified above. A more specific preparation method may be the method disclosed in Chinese Patent Application No. 201010223282.3, which is incorporated herein by reference in its entirety.
Example 1: Preparation and Stability Test of the Composition
[0064] 5 wt % human serum albumin solution (HSA), copper sulfate solution (CuSO.sub.4) of different concentrations as shown in Table 1 below and 5 wt % dextrose solution were mixed in a volume ratio of 3:1:9, and about 76.077 mL of perfluoropropane was filled into the mixed solution, and then the liquid-gas mixture was sonicated using an ultrasonic crusher (30% of the amplitude acts for 120 seconds, 80% of the amplitude acts for 30 seconds) to obtain a mixture of the present application, which is stored at 4° C.
[0065] The stability of the microbubble solution system was observed during storage at 4° C., wherein if microbubbles ruptured within 5 hours of standing, the microbubble solution system was considered extremely unstable (represented by X X); if microbubbles ruptured within 12 hours of standing, the microbubble solution system was considered unstable (represented by X); if microbubbles ruptured within 24 hours of standing, the microbubble solution system was considered stable (represented by Δ); if microbubbles did not rupture after standing for 1 to 3 months, the microbubble solution system was considered to be better in stability (represented by ◯); and if microbubbles did not rupture after standing for 3 months or more, the microbubble solution system was considered to be excellent in stability (represented by ⊚).
[0066] The colors of each obtained solutions were compared with the color plate, and the colors were qualitatively determined, and the storage stability was also observed. The results are shown in Table 1.
TABLE-US-00001 TABLE 1 Color quality and stability of albumin-copper sulfate complex Concentration of the Color No. CuSO.sub.4 solution description Color code Stability 1 0.5 mg/mL Light fresh FFCCCC ◯ pink 2 0.8 mg/mL Fresh pink FF99CC 3 1.0 mg/mL Periwinkle FF99FF ⊚ 4 1.2 mg/mL Impatiens FF66FF ◯ pink 5 1.25 mg/mL Lotus FF66CC ◯ 6 1.3 mg/mL Dark pink FF6699 ◯ 7 1.35 mg/mL Vivid pink CC3366 ◯ 8 1.4 mg/mL Red lotus CC6699 Δ gray 9 1.45 mg/mL Cockscomb 993399 Δ red 10 1.5 mg/mL Green lotus 993366 X 11 2.0 mg/mL Dark reddish 6633FF X purple 12 3.0 mg/mL Cobalt blue 3366CC XX
[0067] The results showed that the prepared copper-albumin microbubble solution system was pink and had good stability. Among them, the microbubble system prepared from 1.0 mg/mL CuSO.sub.4 was the most stable and could be stably stored for more than 3 months in a refrigerator at 4° C. While the microbubble system prepared from 1.5 mg/mL, 2.0 mg/mL CuSO.sub.4 solution was not stable enough, and the microbubbles ruptured after standing overnight; the copper-albumin microbubbles prepared from 3.0 mg/mL CuSO.sub.4 solution had the worst stability, and the microbubbles ruptured after standing for 2 hours.
[0068] The particle size distribution and concentration of each batch of microbubbles were further detected, and it was found that the particle size distribution and concentration were uniform among all batches of the pink series microbubble system. The differences in particle size distribution and concentration between batches of other color systems are large. Referring to
[0069] It has been found by this stability example that a stable microbubble system can be obtained by mixing the albumin-containing solution and the copper ion-containing solution in an appropriate concentration and ratio, and the particle size of the microbubbles in the system fluctuates from batch to batch.
Example 2: Preparation of the Compositions of the Present Invention
[0070] 5 wt % human albumin solution and 1 mg/mL copper sulfate solution were mixted in a ratio of 3:1, and then 76.077 mL of perfluoropropane was quantitatively filled into the albumin-copper sulfate mixed solution, and then the liquid-gas mixture was sonicated using an ultrasonic crusher (20 KHz) until the mixture becomes a pale pink emulsion suspension. Finally, it was detected that the average particle size of the microbubbles in the composition solution was about 1.05 μm, and the copper concentration was about 48.88±4.647 μg/mL. The resulting solution was stored at 4° C. and used in the following examples.
[0071] 5 wt % human serum albumin solution and 5 wt % dextrose solution were mixed in a ratio of 3:1, and then 38.04 mL of perfluoropropane was quantitatively filled into the 5% albumin-5% dextrose solution, and then the liquid-gas mixture was sonicated using an ultrasonic crusher (20 KHz) until the mixture becomes a white milky suspension. Finally, the average particle size of microbubbles and the average concentration of microbubbles in the composition solution were measured to be about 0.839 μm and 2.93×10.sup.7/mL, respectively.
[0072] The resulting solution was stored at 4° C. and used in the following examples.
Example 3: Establishment of Rabbit Atherosclerosis Model
[0073] In this experiment, high-cholesterol diet feeding method was adopted, and the high cholesterol feed was prepared by the Farm of Sichuan Experimental Animal Committee. The specific method is as follows: 1% by mass of cholesterol granules were added into the crushed common feed, mixed and then re-compressed into the granular feed containing high cholesterol. New Zealand white rabbits are sensitive to high cholesterol diets, and simply increasing the cholesterol in the diet can induce the formation of atherosclerotic lesions in animals, and the pathological process is similar to the pathological process of human in pathophysiology. Besides, diet induction without other intervention can better simulate human beings. Rabbit atherosclerosis model was established by feeding New Zealand white rabbits with the above-mentioned high cholesterol diet for 12 weeks.
[0074] Plaque formation in the aorta, cardiac lesions, copper loss in blood vessels and organs, and serum lipid content of normally fed animals and animals fed with high cholesterol diet were detected after modeling according to the sampling and determination method in Example 4 below.
[0075] Among them, Oil Red O staining of the abdominal aorta and thoracic aorta could clearly show that obvious red bulging plaques were visible under the intima of the abdominal aorta and thoracic aorta in rabbits fed with high cholesterol diet, while the intima of the thoracic aorta in rabbits fed with normal diet was smooth, and no plaque formation was seen (see
[0076] The aortic adventitia was peeled off, and the copper content of the aortic intima-media was determined by atomic absorption spectrometry, it was found that the copper content in the aorta of the high-cholesterol diet group was significantly decreased (by about 39%) as compared with that of the normal diet group (see
[0077] In addition, referring to
[0078] Thus proving the success of modeling.
Example 4: Effect of the Composition of the Present Invention on Atherosclerotic Plaque
Grouping and Processing Method:
[0079] After one week of adaptive feeding, 44 New Zealand white rabbits were randomly assigned into a normal diet group (n=11) and an atherosclerotic lesion group (n=33) according to body weight. Rabbit atherosclerosis model was established by feeding with high cholesterol diet for 12 weeks. After modeling, the rabbits were randomly assigned into four groups according to body weight, in which one group being the pre-intervention group (AS & pre-intervention, n=7), and meanwhile, 5 rabbits in the normal diet group were randomly selected according to body weight to be compared with the pre-intervention group (normal-1 group). The materials were collected from the two groups immediately after modeling. The remaining three groups were non-intervention groups (AS & non-intervention, n=8), Cu-microbubble group (AS & Cu-MB+US, n=9), and microbubble group (AS & MB+US, n=9). The remaining normal diet groups were designated as normal groups (n=6). Detailed process and grouping are shown in
[0080] Intervention Method:
[0081] The rabbits were fixed on the fixation plate in the supine position and the abdominal coat was removed. During the intervention, 5 mL of reagent was injected in five times, with a rapid bolus of 1 mL each time, and at the same time, ultrasound with a mechanical index of 1.2 (Philips iU22 probe L9-3) was used to target rupture at the abdominal aorta about 5 cm away from the celiac trunk for release, the release time per milliliter of reagent is 1 minute. The intervention was terminated after the complete release of the reagent was observed by ultrasound imaging. The AS & MB+US group and the AS & Cu-MB+US group were intervened once every three days, with 8 interventions as a cycle, a total of three cycles (24 times in total). AS & non-intervention group only repeated the operation of immobilizing rabbits without any liquid injection.
[0082] Sampling and Determination Method:
[0083] After the animals were weighed and blood collected at the end of the experiment, the materials were collected.
[0084] Blood collection: Fasting blood was collected from middle auricular arteries of rabbits.
[0085] Aorta: Animals were anesthetized to death by an overdose of sodium pentobarbital (1.5 mL/kg dose) via the auricular vein. The rabbit was cut along the midline of the rabbit's abdomen to expose the abdomen, and then the aorta was peeled off. The four branches of the celiac trunk, the superior mesenteric artery, the right renal artery and the left renal artery were ligated in turn to mark the location and prevent major bleeding. After thoracotomy, the entire aorta was further taken out, and the blood vessels were rinsed in normal saline until pale yellow. The thoracic and abdominal aorta are bounded by the diaphragm.
[0086] Tissue allocation of the aorta: the blood vessel was cut into three sections with a blade (
[0087] Serum Biochemical Analysis: blood samples were analyzed for total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) and triglycerides (TG) by colorimetry.
[0088] Oil Red O staining of fresh tissue (gross ORO staining): after the tissue was fixed in paraformaldehyde for 10 minutes, it was stained with ORO. After staining, the aortic intima was peeled off, with the plaque-containing intima facing upward, and the Stereoscopic observation was performed, pictures were collected, and Photoshop software was used to measure the intimal area and plaque area.
[0089] Oil Red O staining of frozen sections: the frozen sections were stained with ORO staining solution and counterstained with hematoxylin Immediately after mounting, the plaques were observed and photographed under a microscope. Image Pro-Plus 6.0 software was used to measure the plaque area and ORO positive area, and the ratio of the positive area to the total plaque area was calculated.
[0090] Sirius Red-Fast Green FCF staining: the paraffin sections were stained with Sirius Red-Fast Green FCF staining solution. After mounting, 100× microscope was used to observe and take pictures. Image Pro-Plus 6.0 software was used to measure the plaque area and Sirius Red positive area, and the ratio of the positive area to the total plaque area was calculated.
[0091] Elastic fiber staining: the paraffin sections were dyed black with Verhoff's working solution, and color separation was conducted with 2% ferric chloride color separation solution to make the elastic fibers black and other components gray. Finally, the resultants were counterstained in VG staining solution to make the background light red Images were collected under a microscope immediately after mounting.
[0092] Immunohistochemical processing immunohistochemical processing was performed according to the conventional method, and the sections after sealing could be stored at room temperature. The images were observed and taken under a 100-fold microscope. Image Pro-Plus 6.0 software was used to outline the morphology of the plaques, and statistical analysis on the size of the positive expression areas in the plaques was performed.
[0093] Detection of copper concentration: the concentrations of copper in serum and tissues were determined by atomic absorption spectrometry (Atomic Absorption Spectroscopy, ICE3500, Thermo Corporation).
[0094] Detection of lipid content in abdominal aorta: the contents of total cholesterol (TC), sphingomyelin (SM), free fatty acid (FFA) and triglyceride (TG) in abdominal aorta were detected by colorimetry.
[0095] Plaque vulnerability index: studies suggest that macrophages and lipids in plaques are components that promote the instability of plaques, while smooth muscle cells and collagen are components that promote cell stability. Therefore, the vulnerability index of plaques was calculated according to the following formula:
Plaque vulnerability index=(macrophages %+lipid components %)/(smooth muscle cells %+collagen %).
[0096] Data processing and statistical analysis: all experimental data in this study were analyzed using SPSS 20.0 statistical analysis software. Student t test was used for univariate analysis of the two groups, and One-way ANOVA was used to compare the non-intervention group (AS & non-intervention), the microbubble group (AS & MB+US) and the Cu-microbubble group (AS & Cu-MB+US). When the differences of three groups in One-way ANOVA comparison were statistically significant, further comparison between two groups shall be conducted by SNK. When the data did not conform to the normal distribution, the rank sum test was used, with α=0.05 as the test level, and p<0.05 was considered statistically significant.
[0097] Test Results:
4.1. Changes in Atherosclerotic Plaque Size
4.1.1 Changes in Percentage of Atherosclerotic Plaque Area
[0098] After modeling, intervention was performed according to the aforementioned intervention method, and the percentage of plaque area relative to vascular tiled area was calculated according to the results of Oil Red O staining. The results are shown in Table 2 below. In addition, the statistical results of plaque areas in each group of abdominal aorta part are shown in
TABLE-US-00002 TABLE 2 AS & pre- AS & non- AS & AS & Cu- Plaque location intervention intervention MB + US MB + US Plaque Abdominal 41.57% 80.96% 87.58% 51.63% area aorta Thoracic 68.42% 83.29% 89.59% 57.75% aorta
[0099] As shown in Table 2 and
4.1.2 Cross-Sectional Area of Atheroma
[0100] The elastic fiber EVG-stained section of the abdominal aortic cross-section was further observed (see
[0101] As shown in
[0102] The above results indicated that Cu ion played a vital role in inhibiting the growth of plaques and reducing the size of plaques. Only the cavitation of the microbubbles themselves at the lesion site has little inhibition on the growth of plaques.
4.2. Plaque Stability Changes
4.2.1. Change in Lipid Composition in Plaques
[0103] The Oil Red O lipid-stained sections of the abdominal aorta were observed (see
[0104] As shown in
[0105] The amounts of total cholesterol (TC), sphingomyelin (SM), free fatty acid (FFA) and triglyceride (TG) in abdominal aorta of each group were further detected and statistically analyzed, as shown in
4.2.2. Changes in Collagen Composition in Plaques
[0106] The sections of each group stained with Sirius Red-Fast Green FCF were observed, in which red indicates the collagen component (see
[0107] Among them, compared with the pre-intervention group (AS & pre-intervention), the collagen content in the non-intervention group (AS & non-intervention) was significantly increased, the collagen contents in the microbubble group (AS & MB+US) and Cu-microbubble group (AS & Cu-MB+US) were further increased, and the Cu-microbubble group showed an increasing trend compared with the microbubble group, with a growth rate of 17.14%.
[0108] It is generally believed that the more collagen component in plaques, the better for the stability of plaques. From the results of the respective experiments mentioned above, it could be seen that the collagen components in the microbubble group and the Cu-microbubble group were slightly increased.
4.2.3. Changes in the Proportion of Smooth Muscle Cells in Plaques
[0109] The smooth muscle cells were indicated by using α-SMA as a marker by using frozen section immunohistochemistry. The ratio of the area of smooth muscle cells in the plaque to the area of the plaque (the portion surrounded by the dotted line in
[0110] It is generally believed that the more smooth muscle in the plaque, the better the stability of the plaque. It can be seen from the results of the respective experiments described above that the composition of the present invention has no effect on smooth muscle.
4.2.4. Changes in the Proportion of Macrophages in Plaques
[0111] Using paraffin section immunohistochemistry, CD68 was used as a marker to indicate the macrophages (see
[0112] It is generally believed that the fewer macrophages in the plaque, the better the stability of the plaque. As can be seen from the results of the respective experiments described above, the composition of the present invention has no significant effect on the number of macrophages.
4.2.5. Variation of Fibrous Cap Thickness in Plaques
[0113] The smooth muscle cells were indicated by using α-SMA as a marker by using frozen section immunohistochemistry. The thickness of the fibrous cap was indicated by the distribution on the side near the lumen of the plaque where the smooth muscle cells were located. The ratio of the thickness of the fibrous cap in the plaque (the narrower part enclosed by the dotted line in
[0114] In general, the change in the thickness of the fibrous cap is an indicator of the change in plaque structure. The larger the ratio of the fibrous cap thickness to the plaque thickness, the more stable the plaque. It can be seen from
4.2.6. Changes in Plaque Vulnerability Index
[0115] The vulnerability index of the plaque was calculated basing on the parameters measured in 4.2.1 to 4.2.4 above. The vulnerability index of plaques is calculated according to the following formula:
Plaque vulnerability index=(macrophages %+lipid components %)/(smooth muscle cells %+collagen %).
[0116] In the above formula, macrophages %, lipid components %, smooth muscle cell % and collagen % are the percentages of the areas of macrophages, lipid components, smooth muscle cells and collagen measured above in the plaque area, respectively. The calculated average plaque vulnerability index of each group is shown in Table 3 below.
TABLE-US-00003 TABLE 3 Pre- Non- Cu- intervention intervention Microbubble microbubble Group group group group group Plaque 0.415 0.239 0.264 0.196 vulnerability index
Example 5: Effect of the Composition of the Present Invention on Coronary Atherosclerotic Plaque
[0117] Establishment of rabbit atherosclerosis model in this Example is the same as that in Example 3, and the microbubble composition used was prepared in Example 2.
[0118] 8 New Zealand white rabbits were treated in a similar manner as in Example 4, and divided into a non-intervention group (AS & non-intervention) (n=3) and a Cu-microbubble group (AS & Cu-MB+US)(n=5).
[0119] Sampling Method is as Follows:
[0120] Coronary Artery Sampling:
[0121] Sampling of left coronary artery: the left main coronary artery and left anterior descending branch were separated from the aortic root to the apex, and the total length of sampling was about 1.3 cm, in which the left coronary artery of 0.3 cm near the aortic root was used for pathological sectioning, and the remaining about 1 cm was used for gross ORO analysis.
[0122] Right coronary artery sampling: the right coronary artery was separated from the aortic root to the right ventricle, and the total length of the sampling was about 1.3 cm, in which the right coronary artery of 0.3 cm close to the aortic root was used for pathological sectioning, and the remaining about 1 cm was used for gross ORO analysis.
[0123] Test Results:
5.1 Changes in Atherosclerotic Plaque Size
5.1.1 Change in Percentage of Atherosclerotic Plaque Area
[0124] After modeling, intervention was performed according to the aforementioned intervention method, and the percentage of plaque area relative to vascular tiled area was calculated according to the results of Oil Red O staining. The results are shown in Table 4 below. In addition, the statistical results of plaque areas in each group of left and right coronary arteries are shown in
TABLE-US-00004 TABLE 4 AS & AS & Plaque position non-intervention Cu-MB + US Left coronary artery 52.69% 17.86% Right coronary artery 79.92% 43.87%
5.2 Plaque Stability Changes
5.2.1. Changes in Lipid Composition in Plaques
[0125] The Oil Red O lipid-stained sections of the abdominal aorta were observed (see
5.2.2 Changes in Collagen Composition in Plaques
[0126] The sections stained with Sirius Red-Fast Green FCF were observed in the left coronary vein (see
[0127] It is generally believed that the more collagen component in plaques, the better for the stability of plaques. From the results of the respective experiments mentioned above, it could be seen that the collagen components in the Cu-microbubble group was doubled compared with that in the non-intervention group.
[0128] 5.2.3 Changes in the proportion of smooth muscle cells in plaques
[0129] The stained sections of smooth muscle cells in the cross section of the left coronary artery were observed (see
[0130] It is generally believed that the more smooth muscle in the plaque, the better the stability of the plaque. It can be seen from the results of the respective experiments described above that the smooth muscle cell composition was increased by approximately 60% in the Cu-microbubble group (AS & Cu-MB+US) compared with the non-intervention group.
5.2.4 Changes in the Proportion of Macrophages in Plaques
[0131] The stained sections of macrophages in the cross section of the left coronary artery were observed (see
[0132] It is generally believed that the fewer macrophages in the plaque, the better the stability of the plaque. As can be seen from the results of the respective experiments described above, the composition of the present invention has no significant effect on the number of macrophages.
[0133] It can be seen that the intervention of the composition of the present invention combined with ultrasonic treatment does not affect the stability of the plaque and has a trend of enhancing the stability of the plaque, while the simple microbubbles combined with ultrasonic treatment has a trend of reducing the stability of the plaque. This result suggested that, unlike the previous proposal of using microbubble cavitation to break up plaques, the effect of Cu ions on plaques may be to reduce plaques in situ and prevent plaques from shedding to some extent.
[0134] The above description are only preferred embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Under the inventive concept of the present invention, the equivalent structure transformation made by the contents of the description and drawings of the present invention, or directly/indirectly applied to other relevant technical fields are all included in the scope of patent protection of the present invention.